---
title: "BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference | BYSI Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275315920.md"
description: "BeyondSpring Inc. (NASDAQ: BYSI) will participate in the Immuno-Oncology 360° Conference from February 10-12, 2026, in Boston, MA. Dr. Lan Huang, CEO, will present on Plinabulin, focusing on its role in enhancing PD-1/PD-L1 blockade and its unique mechanism of action. The presentation is scheduled for February 11, 2026, at 4:55 PM ET. Slides will be available on the company’s website post-presentation. BeyondSpring is developing Plinabulin as an anti-cancer agent for NSCLC and other indications, addressing significant medical needs."
datetime: "2026-02-09T04:15:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275315920.md)
  - [en](https://longbridge.com/en/news/275315920.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275315920.md)
generator: "portal-rs"
---

# BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference | BYSI Stock News

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- **BeyondSpring Inc.** (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360° (IO360°) Conference 2026, held February 10-12, 2026 in Boston, MA.

Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD blockade and highlight Plinabulin’s unique mechanism of action and clinical development strategy.

**Presentation Details:**  
Title: Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin  
Track Number: 1. Translational Science & Biomarkers – Expanding Therapeutic Horizons  
Date: Wednesday, February 11, 2026  
Time: 4:55PM to 5:10PM ET  
Location: Sheraton Boston Hotel, Track 1, Grand Ballroom

Following the presentation, the slides will also be available on the “Posters and Presentations” page of the Company’s website.

**About BeyondSpring**  
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. Learn more at https://beyondspringpharma.com.

**Investor Contact:** IR@beyondspringpharma.com  
**Media Contact:** PR@beyondspringpharma.com

### Related Stocks

- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BYSI.US](https://longbridge.com/en/quote/BYSI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md)
- [BeyondSpring posts investor deck highlighting plinabulin late-stage NSCLC program and immune-modulating approach](https://longbridge.com/en/news/296010507.md)
- [BeyondSpring Q2 FY26 net loss narrows to $1.8 million; cash falls to $6.5 million](https://longbridge.com/en/news/295977996.md)
- [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**